

Specialty Guideline Management

Ryplazim

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

| Brand Name | Generic Name |
|------------|-------------------------|
| Ryplazim | plasminogen, human-tvmh |

Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications¹

Ryplazim is plasma-derived human plasminogen indicated for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenemia).

All other indications are considered experimental/investigational and not medically necessary.

Documentation

Submission of the following information is necessary to initiate the prior authorization review:

- Initial Requests: Medical records (e.g., chart notes, lab reports) documenting a baseline plasminogen activity level and a history of lesions and symptoms consistent with diagnosis.
- Continuation Requests: Medical records (e.g., chart notes, lab reports) documenting disease stability or improvement.

Coverage Criteria

Plasminogen Deficiency Type 1 (hypoplasminogenemia)¹⁻³

Authorization of 12 months may be granted for treatment of plasminogen deficiency type 1 (hypoplasminogenemia) when all of the following criteria are met:

- Member has a baseline plasminogen activity level of 45% or less.
- Member has a documented history of lesions and symptoms consistent with a diagnosis of plasminogen deficiency type 1 (e.g., ligneous conjunctivitis, ligneous gingivitis or gingival overgrowth, vision abnormalities, respiratory distress and/or obstruction, abnormal wound healing).

Continuation of Therapy

Authorization of 12 months may be granted for members with an indication listed in the coverage criteria section who are experiencing benefit from therapy as evidenced by disease stability or disease improvement (e.g., improvement in lesion number and/or size, absence of new lesion development, improvement in respiratory function, increased quality of life).

References

1. Ryplazim [package insert]. Fort Lee, NJ: Prometic Biotherapeutics Inc.; January 2024.
2. Shapiro AD, Nakar C, Parker JM, et al. Plasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiency. *Blood*. 2018;131(12):1301-1310.
3. Celkan T. Plasminogen deficiency. *J Thromb Thrombolysis*. January 2017; 43(1):132-138.